Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Low Bone Mass Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

NCT06250283
View directory record Official record
Conditions
Low Bone Mass
Interventions
Resveratrol, Placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults

NCT03761979
View directory record Official record
Conditions
Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
Interventions
Strontium L-lactate
Dietary Supplement
Lead sponsor
BioLink Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated Phase 4 Interventional Results available

Denosumab in Primary Hyperparathyroidism

NCT01558115
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

NCT00759772
View directory record Official record
Conditions
Anorexia Nervosa, Osteoporosis
Interventions
Placebo, Teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Jul 23, 2026, 10:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Age Related Changes in Calciotropic Hormones and Their Impact on Male Osteoporosis

NCT00588874
View directory record Official record
Conditions
Low Bone Density
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
50 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 4 Interventional Results available

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2541546 in Women With Low Bone Mineral Density

NCT01144377
View directory record Official record
Conditions
Osteoporosis
Interventions
LY2541546, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Gainesville, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 23, 2026, 10:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Low Energy Availability, Menstrual Irregularity, and Low Bone Mass

NCT01059968
View directory record Official record
Conditions
Bone Density, Energy Availability
Interventions
Not listed
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
15 Years to 17 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 3 Interventional

To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women

NCT00145275
View directory record Official record
Conditions
Osteopenia
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 75 Years · Female only
Enrollment
455 participants
Timeline
2004 – 2005
U.S. locations
6
States / cities
Unavailable, Georgia • Unavailable, Illinois • Unavailable, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 3 Interventional

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

NCT00088010
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years · Female only
Enrollment
9,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Elk Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

NCT04366726
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide-sMTS
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

NCT03227458
View directory record Official record
Conditions
Low Bone Mass, Osteoporosis, Postmenopausal
Interventions
DHEA, Placebo, Exercise
Other · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"VIBES"--Low Magnitude Mechanical Stimulation to Improve Bone Mineral Density

NCT00396994
View directory record Official record
Conditions
Osteopenia
Interventions
Low magnitude mechanical stimulation, Sham low magnitude mechanical stimulation
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
60 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 4 Interventional Results available

Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass

NCT00489424
View directory record Official record
Conditions
Osteoporosis
Interventions
Placebo, Acetaminophen, Fluvastatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 79 Years · Female only
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Http://www.osteoporosisclinicalresearch.com, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density

NCT00715676
View directory record Official record
Conditions
Osteoporosis
Interventions
Placebo, DP001
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Upland, California • Indianapolis, Indiana • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2010 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Results available

Transition From Alendronate to Romosozumab (AMG 785)

NCT01588509
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

NCT01406548
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jul 23, 2026, 10:07 AM EDT
Completed No phase listed Observational Results available

Alendronate in Juvenile Osteoporosis

NCT00920075
View directory record Official record
Conditions
Juvenile Osteoporosis, Low Bone Density, Fractures
Interventions
Alendronate (Fosamax)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
8 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 4 Interventional Results available

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444
View directory record Official record
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplements for HIV-positive Patients on cART

NCT01295034
View directory record Official record
Conditions
HIV-associated Co-morbidities
Interventions
conventional vitamin D treatment, tiered/titrated vitamin D dosing
Dietary Supplement · Drug
Lead sponsor
Andrea Branch
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Self Regulated Physical Activity and Bone Growth Enhancement in Premature Infants

NCT03884322
View directory record Official record
Conditions
Prematurity, VLBW - Very Low Birth Weight Infant
Interventions
Prepod, Joint compression exercises
Other · Procedure
Lead sponsor
Asante Health System
Other
Eligibility
32 Weeks to 36 Weeks
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Not applicable Interventional

Effects of DHEA and Exercise on Bone Marrow Fat in Postmenopausal Women

NCT05316272
View directory record Official record
Conditions
Low Bone Density, Osteoporosis
Interventions
Exercise, DHEA
Behavioral · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis

NCT00000430
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Alendronate, Estrogen/progestin therapy
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
60 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 3, 2007 · Synced Jul 23, 2026, 10:07 AM EDT